Home|Journals|Articles by Year|Audio Abstracts
 

Original Article



ZnO Nanoparticles: Crosslink between cytotoxicity on liver cell lines and In Vivo biosafety on different mice organs

Nahla Nabil Kamel, Maha Zaki Rizk, Walaa Gamal Hozayen, Abdel-Hamid Zaki Abdel-Hamid.




Abstract
Cited by 0 Articles

Zinc oxide nanoparticles (ZnO NPs) have been widely used in several biomedical aspects. This study aimed to explore the cytotoxic effect of different sizes (14nm, 30 nm and 50nm) of ZnO NPs on liver cancer cell lines (HepG2, HuH7 cells) vs normal cells (THLE2 cells).
The cytotoxicity, oxidative stress and apoptosis induced by well-characterized ZnO NPs were investigated by MTT and multiple assays.
The results showed that the IC50 values on HepG2 and HuH7 recorded variable cytotoxic effects for different sizes whereas no cytotoxic effect was observed on THLE2. The highest cytotoxic activity was recorded for particle size 14 nm. The oxidative stress elicited a reduction in glutathione reduced with increase in lipid peroxides and Caspase-3. In addition, RT-PCR revealed a significant up- regulation in caspase-3 gene expression. In vivo histopathological investigation confirmed the biosafety of the same particle size (14 nm) which revealed the least toxic effect on all mice organs.
In conclusion, ZnO NPs could be useful in future therapeutic applications on liver cancer.

Key words: ZnO nanoparticles, HepG2 cells, HuH7, liver cancer, cytotoxicity






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.